Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Rating of “Buy” from Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been given an average recommendation of “Buy” by the fifteen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $209.1429.

Several brokerages have recently commented on PVLA. Wall Street Zen lowered shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st.

Insider Activity

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. The trade was a 66.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Partners Public Asset Management LLC boosted its stake in shares of Palvella Therapeutics by 1,016.0% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after purchasing an additional 354,525 shares during the period. Vanguard Group Inc. increased its stake in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares during the period. State Street Corp increased its stake in Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after buying an additional 283,211 shares during the period. Jennison Associates LLC increased its stake in Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after buying an additional 280,573 shares during the period. Finally, First Light Asset Management LLC lifted its holdings in Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after buying an additional 271,617 shares in the last quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $154.93 on Friday. The firm’s 50-day moving average is $132.97 and its two-hundred day moving average is $119.75. Palvella Therapeutics has a 12 month low of $37.33 and a 12 month high of $161.38. The stock has a market capitalization of $2.23 billion, a P/E ratio of -32.08 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). As a group, analysts anticipate that Palvella Therapeutics will post -5.58 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.